University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, UNC School of Medicine, Chapel Hill.
Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill.
JAMA. 2024 Nov 12;332(18):1559-1573. doi: 10.1001/jama.2024.16338.
More than 3.5 million people worldwide and 540 000 individuals in the US receive maintenance hemodialysis or peritoneal dialysis for the treatment of chronic kidney failure. The 5-year survival rate is approximately 40% after initiation of maintenance dialysis.
Hemodialysis and peritoneal dialysis remove metabolic waste and excess body water and rebalance electrolytes to sustain life. There is no recommended estimated glomerular filtration rate (eGFR) threshold for initiating dialysis, and patient-clinician shared decision-making should help determine when to initiate dialysis. Persistent signs and symptoms of uremia (eg, nausea, fatigue) and volume overload (eg, dyspnea, peripheral edema), worsening eGFR, metabolic acidosis, and hyperkalemia inform the timing of therapy initiation. A randomized clinical trial reported no mortality benefit to starting dialysis at higher eGFR (10-14 mL/min/1.73 m2) vs lower eGFR (5-7 mL/min/1.73 m2) levels. Observational data suggested no differences in 5-year mortality with use of hemodialysis vs peritoneal dialysis. Cardiovascular (eg, arrhythmias, cardiac arrest) and infection-related complications of maintenance dialysis are common. In the US, hemodialysis catheter-related bloodstream infections occur at a rate of 1.1 to 5.5 episodes per 1000 catheter-days and affect approximately 50% of patients within 6 months of catheter placement. Peritonitis occurs at a rate of 0.26 episodes per patient-year and affects about 30% of individuals in the first year of peritoneal dialysis therapy. Chronic kidney failure-related systemic complications, such as anemia, hyperphosphatemia, hypocalcemia, and hypertension, often require pharmacologic treatment. Hypotension during dialysis, refractory symptoms (eg, muscle cramps, itching), and malfunction of dialysis access can interfere with delivery of dialysis.
In 2021, more than 540 000 patients in the US received maintenance hemodialysis or peritoneal dialysis for treatment of chronic kidney failure. Five-year survival rate after initiation of maintenance dialysis is approximately 40%, and the mortality rate is similar with hemodialysis and peritoneal dialysis. Decisions about dialysis initiation timing and modality are influenced by patient symptoms, laboratory trajectories, patient preferences, and therapy cost and availability and should include shared decision-making.
全球有超过 350 万人和美国有 54 万人接受维持性血液透析或腹膜透析来治疗慢性肾衰竭。开始维持性透析后的 5 年生存率约为 40%。
血液透析和腹膜透析清除代谢废物和多余的身体水分,并重新平衡电解质以维持生命。目前没有推荐的开始透析的肾小球滤过率(eGFR)阈值,患者与临床医生共同决策应该有助于确定何时开始透析。持续的尿毒症(如恶心、疲劳)和容量超负荷(如呼吸困难、外周水肿)、eGFR 恶化、代谢性酸中毒和高钾血症等迹象和症状会影响治疗开始的时间。一项随机临床试验报告称,在更高的 eGFR(10-14 毫升/分钟/1.73 平方米)与较低的 eGFR(5-7 毫升/分钟/1.73 平方米)水平开始透析并没有带来死亡率的获益。观察性数据表明,血液透析与腹膜透析在 5 年死亡率方面没有差异。维持性透析的心血管(如心律失常、心脏骤停)和感染相关并发症很常见。在美国,血液透析导管相关血流感染的发生率为每 1000 个导管日 1.1 至 5.5 例,并且在导管放置后 6 个月内约影响 50%的患者。腹膜炎的发生率为每年每患者 0.26 例,并且影响到腹膜透析治疗第一年约 30%的个体。慢性肾衰竭相关的全身并发症,如贫血、高磷血症、低钙血症和高血压,通常需要药物治疗。透析过程中的低血压、难治性症状(如肌肉痉挛、瘙痒)和透析通路故障会干扰透析的进行。
2021 年,美国有超过 54 万人接受维持性血液透析或腹膜透析治疗慢性肾衰竭。开始维持性透析后的 5 年生存率约为 40%,血液透析和腹膜透析的死亡率相似。透析启动时机和方式的决策受到患者症状、实验室轨迹、患者偏好、治疗成本和可用性的影响,并且应该包括共同决策。